{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001841","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.705838+00:00","generated_at":"2026-06-07T10:25:57.292976+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aldeyra announces positive Phase 2 data for ADX-629 in atopic dermatitis; advancing ADX-246","bullets":["Phase 2 trial of ADX-629 in 8 mild-to-moderate atopic dermatitis patients showed statistically significant improvement from baseline in EASI (p=0.0006) and IGA (p<0.0001).","Three patients (38%) achieved EASI-75; one patient (13%) had complete clearance of affected body surface area; two patients (25%) reported elimination of itching.","Only two mild treatment-related adverse events reported; no serious adverse events or discontinuations. All eight patients completed the trial.","Company plans to initiate a randomized placebo-controlled Phase 1/2 trial of ADX-246 in H1 2024, with topline results expected in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001841","json":"https://secwatch.observer/filing/0001157523-23-001841.json","markdown":"https://secwatch.observer/filing/0001157523-23-001841.md","text":"https://secwatch.observer/filing/0001157523-23-001841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323001841/0001157523-23-001841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323001841/a53872843.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:25:57.292976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}